# Alpha-9 Oncology

Source: https://onco.cc/companies/alpha-9-oncology/  
OnCo record `alpha-9-oncology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Alpha-9 Oncology designs bespoke molecules that deliver radioactive isotopes to cancer cells, with early human trials under way in melanoma and in breast and other solid tumours.

## Summary

Alpha-9 Oncology is a clinical-stage radiopharmaceutical company with offices in Vancouver and Boston. It takes a modular approach, optimising each element of a radiotherapeutic (binder, linker, chelator and isotope) and pairing therapeutic agents with imaging companions. A9-3408, an actinium-225 radiotherapeutic targeting melanocortin 1 receptor (MC1R), began a phase 1 study in melanoma in December 2025, following the 68Ga imaging agent A9-3202 that entered the clinic in 2024. In September 2026 the company dosed the first patient in a phase 1 study of two GRPR-targeting compounds, 225Ac-A9-0642 and 177Lu-A9-0631, in breast cancer and other solid tumours, with data expected in late 2027. Alpha-9 has an actinium-225 supply agreement with ITM (April 2025). In October 2024 it closed an oversubscribed USD 175 million Series C led by Lightspeed Venture Partners and Ascenta Capital. Paul Blanchfield was appointed CEO in November 2025.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Vancouver
- Type: radiopharma
- Website: https://www.a9oncology.com/

## Notes

- The older domain alpha9oncology.com is now parked; current site is a9oncology.com. Earlier rounds not fetched.

## Sources

- Official website: https://www.a9oncology.com/
- Series C press release: https://www.a9oncology.com/alpha-9-oncology-inc-announces-175-million-oversubscribed-series-c-financing-to-advance-robust-clinical-pipeline-of-radiopharmaceuticals/
- GRPR phase 1 first patient dosed: https://www.a9oncology.com/alpha-9-oncology-doses-first-patient-in-phase-1-clinical-trial-evaluating-grpr-targeted-radiotherapeutics-across-multiple-solid-tumors/

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [PET (positron emission tomography)](https://onco.cc/technologies/pet/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/)
- companies: [Andreessen Horowitz Bio + Health](https://onco.cc/companies/a16z-bio-health/), [Frazier Life Sciences](https://onco.cc/companies/frazier-life-sciences/), [General Catalyst](https://onco.cc/companies/general-catalyst/), [Lightspeed Venture Partners](https://onco.cc/companies/lightspeed-venture-partners/), [RA Capital Management](https://onco.cc/companies/ra-capital/), [Samsara BioCapital](https://onco.cc/companies/samsara-biocapital/)

---
JSON: https://onco.cc/api/v1/entities/alpha-9-oncology.json